Acousia Therapeutics, a Germany-based ear disease therapy developer based on research at Eberhard Karls University of Tübingen, has closed a €10m ($11.8m) series B round led by LBBW Venture Capital.

LBBW Venture Capital, an investment subsidiary of banking group Landesbank Baden-Württemberg, was joined by investors including pharmaceutical firm Boehringer Ingelheim’s strategic investment unit, Boehringer Ingelheim Venture Fund (BIVF).

German government-owned development bank KfW, Creathor Ventures and Bregua also took part in the round.

Founded in 2012, Acousia Therapeutics is…